...
首页> 外文期刊>Annals of the New York Academy of Sciences >Alterations in Gytokine Profile and Dendritic Cells Subsets in Peripheral Blood of Rheumatoid Arthritis Patients before and after Biologic Therapy
【24h】

Alterations in Gytokine Profile and Dendritic Cells Subsets in Peripheral Blood of Rheumatoid Arthritis Patients before and after Biologic Therapy

机译:生物治疗前后类风湿关节炎患者外周血中动植物因子谱和树突状细胞亚群的变化

获取原文
获取原文并翻译 | 示例
           

摘要

Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic joint inflammation and continuous immune cell infiltration in the synovium. These changes are linked to inflammatory cytokine release, leading to eventual destruction of cartilage and bone. During the last decade new therapeutic modalities have improved the prognosis, with the introduction of novel biological response modifiers including anti-TNFα CTLA4Ig and, more recently, anti-IL6. In the present study we looked at the immunolog-ical effects of these three forms of therapy. Serum, obtained from patients with RA was analyzed for TNFα, IL6, IL10, IFNy, and VEGF, and in parallel, circulating plasmacytoid and myeloid dendritic cells (DC) were enumerated before and after three infusions of the respective biological treatments. After treatment with anti-IL6, we found a significant reduction of IL6 and TNFα levels and the percentage of both DC subsets decreased. Although the results did not reach statistical significance for anti-TNFα treatment, similar trends were observed. Meanwhile, CTLA4Ig therapy led to the reduction IFNy levels only. None of the treatments modified significantly VEGF or IL10 levels. These findings may explain why patients with RA improve more rapidly on IL-6 therapy than with the other two modalities.
机译:类风湿关节炎(RA)是一种自身免疫性疾病,其特征在于慢性关节发炎和滑膜中持续的免疫细胞浸润。这些变化与炎性细胞因子的释放有关,最终导致软骨和骨骼的破坏。在过去的十年中,通过引入新的生物反应修饰剂(包括抗TNFαCTLA4Ig和最近的抗IL6),新的治疗方式改善了预后。在本研究中,我们研究了这三种疗法的免疫学作用。分析从RA患者获得的血清中的TNFα,IL6,IL10,IFNγ和VEGF,并平行地,在分别输注各自的生物治疗剂之前和之后,计数循环的浆细胞样细胞和髓样树突状细胞(DC)。用抗IL6治疗后,我们发现IL6和TNFα水平显着降低,并且两个DC亚群的百分比均降低。尽管结果未达到抗TNFα治疗的统计学意义,但观察到类似趋势。同时,CTLA4Ig治疗仅导致IFNy水平降低。没有一种治疗能显着改变VEGF或IL10水平。这些发现可以解释为什么RA患者在IL-6治疗上比其他两种方法能更快地得到改善。

著录项

  • 来源
    《Annals of the New York Academy of Sciences》 |2009年第2009期|334-342|共9页
  • 作者单位

    Hospital Albert Einstein-Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, Brazil;

    Hospital Albert Einstein-Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, Brazil Hospital Abreu Sodre -Associagdo de Assistencia a Crianca Deficiente, Sao Paulo, Brazil;

    Hospital Albert Einstein-Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, Brazil Hospital Abreu Sodre -Associagdo de Assistencia a Crianca Deficiente, Sao Paulo, Brazil;

    Hospital Albert Einstein-Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, Brazil;

    Hospital Albert Einstein-Instituto Israelita de Ensino e Pesquisa Albert Einstein, Sao Paulo, Brazil;

    Departamento de Pediatria da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil;

    Tnsti-tuto Israelita de Ensino e Pesquisa Albert Einstein, Av Albert Einstein, 627 2SS, Morumbi Sao Paulo - Brazil Hospital Abreu Sodre -Associagdo de Assistencia a Crianca Deficiente, Sao Paulo, Brazil;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    cytokines; rheumatoid; arthritis; dendritic cell;

    机译:细胞因子类风湿;关节炎;树突状细胞;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号